1. Academic Validation
  2. Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions

Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions

  • Eur J Pharmacol. 2003 Jan 17;459(2-3):113-20. doi: 10.1016/s0014-2999(02)02869-8.
Masahide Nakajima 1 Kazutaka Hayashi Ken-ichi Katayama Yusaku Amano Yasuhiro Egi Masayoshi Uehata Nobuharu Goto Takao Kondo
Affiliations

Affiliation

  • 1 Pharmaceuticals Research Unit, Mitsubishi Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Kanagawa, 227-0033, Yokohama, Japan. [email protected]
Abstract

The signaling pathway of Rho and Rho-associated coiled-coil forming protein kinase (ROCK) is involved in tumor metastasis. In the present study, we investigated the suppressive effect of a novel inhibitor of ROCK, Wf-536 [(+)-(R)-4-(1-Aminoethyl)-N-(4-pyridyl) benzamide monohydrochloride], on spontaneous tumor metastasis in vivo and analyzed its action on tumor cell motility and angiogenesis to clarify its action mechanism. Wf-536 (0.3-3 mg/kg/day) was found to inhibit Lewis lung carcinoma (LLC) metastasis and LLC-induced angiogenesis in orally treated mice; in vitro, it inhibited both invasion and migration by LLC cells and invasion, migration, and formation of capillary-like tubes on Matrigel by endothelial cells, without cytotoxicity or anti-proliferative action in either cell type. We conclude that Wf-536 has tumor anti-metastatic activity which may depend on inhibition of tumor motility and angiogenesis. The findings support its further clinical development as an anti-metastatic agent.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-118837
    ROCK Inhibitor